AI Article Synopsis
- The study aimed to identify actinin-4 protein overexpression as a potential predictive biomarker for the success of platinum-combination adjuvant chemotherapy in patients with stage II-IIIA lung adenocarcinoma.
- Researchers evaluated actinin-4 levels in patients who had their tumors completely removed and compared survival outcomes between those who received adjuvant chemotherapy and those who were only observed.
- Results showed that patients with high actinin-4 levels benefited significantly from adjuvant chemotherapy, while those with low levels did not see a survival advantage, indicating that actinin-4 might help predict who will respond to treatment.
Article Abstract
Aim: Although several clinical trials demonstrated the benefits of platinum-combination adjuvant chemotherapy for stage II-IIIA lung adenocarcinoma, predictive biomarkers for the efficacy of such therapy have not yet been identified. We evaluated protein overexpression of actinin-4 as a predictive biomarker of the efficacy of adjuvant chemotherapy in resected lung adenocarcinoma.
Materials & Methods: We measured actinin-4 protein levels in patients with completely resected stage II-IIIA lung adenocarcinoma using immunohistochemistry and then retrospectively compared survival between adjuvant chemotherapy and observation groups.
Results: A total of 148 eligible patients were classified into actinin-4 positive or negative cases by immunohistochemistry. In the former, patients with adjuvant chemotherapy survived significantly longer than those with observation (hazard ratio [HR]: 0.307; p = 0.028). But, no significant survival benefit was noted with adjuvant chemotherapy (HR: 0.926; p = 0.876) in the latter.
Conclusion: This marker could predict the efficacy of adjuvant chemotherapy for resected lung adenocarcinoma patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/bmm-2017-0150 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary squamous cell carcinoma of the pancreas: A case report.
Int J Surg Case Rep
January 2025
Department of Hepatopancreatobiliary Surgery, First People's Hospital of Jiashan County, Jiaxing, Zhejiang Province, China.
Introduction: Primary squamous cell carcinoma (SCC) is a rare type of pancreatic cancer with an extremely low incidence rate and a prognosis that is poorer than that of pancreatic ductal adenocarcinoma.
Presentation Of Case: We report a case of pure pancreatic SCC in an 80-year-old man. Based on the examination before surgical resection, we did not detect any SCC lesions that might have metastasized to the pancreas.
Neoadjuvant chemotherapy in locally advanced colon cancer: A systematic review with proportional meta-analysis.
Eur J Surg Oncol
December 2024
Department of Medical Oncology, Catharina Hospital, Eindhoven, Netherlands.
Neoadjuvant chemotherapy is suggested in locally advanced colon cancer. Data on improved long-term oncological outcomes are lacking, which hampers the implementation in clinical practice. This systematic review provides an overview of the benefits and drawbacks of neoadjuvant chemotherapy in patients with locally advanced colon cancer.
View Article and Find Full Text PDFExtramedullary plasmacytoma with the uvula as first affected site: A case report.
World J Clin Oncol
January 2025
Department of Hematology, The First Affiliated Hospital of Jishou University, Jishou 416000, Hunan Province, China.
Background: Extramedullary plasmacytoma (EMP) represents one of the rarer forms of plasma cell malignancies, capable of impacting a variety of tissues and organs throughout the body. The majority of EMP cases are predominantly found in the head and neck region, especially within the laryngopharynx, as well as in the gastrointestinal tract. While there have been documented instances of oropharyngeal involvement in EMP cases in the academic literature, it is important to note that EMP specifically affecting the uvula is exceedingly uncommon.
View Article and Find Full Text PDFManagement of intrahepatic cholangiocarcinoma: a review for clinicians.
Gastroenterol Rep (Oxf)
January 2025
Department of Health Sciences, University of Piemonte Orientale, Novara, Italy.
Intrahepatic cholangiocarcinoma (iCCA) is an aggressive liver malignancy that arises from second-order biliary epithelial cells. Its incidence is gradually increasing worldwide. Well-known risk factors have been described, although in many cases, they are not identifiable.
View Article and Find Full Text PDFOptimizing Premenopausal Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer Management in India: Insights From Expert Consensus.
Cureus
December 2024
Department of Medical Affairs, Dr. Reddy's Laboratories, Hyderabad, IND.
This research aims to optimize adjuvant ovarian function suppression (OFS) for premenopausal Indian women with hormone receptor-positive (HR+) /human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (eBC). To address specific challenges identified in clinical practice, a comprehensive questionnaire consisting of 21 statements was developed. These statements were reviewed and validated by a scientific committee, ensuring their accuracy and relevance to the study's objectives.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!